Johannes Waltenberger

Showing 1-3 of 3 articles

Coronary interventions

Real-world experience with a novel biodegradable polymer sirolimus-eluting stent: twelve-month results of the BIOFLOW-III registry

Waltenberger J, Brachmann J, Van der Heyden J, Richardt G, Fröbert O, Seige M, Erglis A, Dewilde W, Winkens M, Hegeler-Molkewehrum C, Klein N, Hoffmann S

February 19, 2016 | 10.4244/EIJY15M03_08

Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial

Duckers H, Houtgraaf J, Hehrlein C, Schofer J, Waltenberger J, Gershlick A, Bartunek J, Nienaber C, Naber C, Macaya C, Peters N, Smits P, Siminiak T, van Mieghem W, Legrand V, Serruys P

February 21, 2011

A European multicentre, randomised study of the MAR-Tyn cobalt chromium tin-coated stent in patients with de novo coronary artery lesions: study design and protocol

Kastrati A, Balducelli M, Di Sciascio G, Moccetti T, Bortone A, Colombo A, Waltenberger J, Hehrlein C

April 12, 2010

1

Latest news

Robotics, AI and Imaging State of The Art; Bleeding Risk and Mortality in CAD; Treating Refractory Angina by Coronary Sinus Narrowing; and more

September 20, 2021

STATE OF THE ART

Robotics, imaging, and artificial intelligence in the catheterisation laboratory

Rafael Beyar et al.

September 20, 2021

ViV TAVI vs repeat SAVR

Monil Majmundar et al.

September 15, 2021

Thrombectomy for ischaemic stroke

Christopher A. Rajkumar et al.

September 10, 2021

Walking the tightrope between ischaemia and bleeding

Michelle L. O’Donoghue et al.

September 20, 2021

Microvascular dysfunction endotypes and outcomes

Christos V. Bourantas et al.

September 20, 2021

Coronary sinus reducer therapy for refractory angina: is it ready for prime time?

Michael Foley et al.

September 20, 2021

Valvular disease